Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Autoimmune Features of Neurodegenerative Disorders
Authors not listed
Columbia University · 2019
Abstract
This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD). The investigators plan to recruit 30 PD, 30 AD/Amnestic Mild Cognitive Impairment (aMCI), and 60 age matched healthy controls in this study to study the role of immune response in PD and AD.
The study involves up to two study visits involving brief questionnaires and blood draw of up to 250cc (approximately 17 tablespoons) to be collected. More ways to participate, including 1) smaller amount blood donation (up to 100cc per visit for 1-2 visits); and 2) participation via tele-visit and mobile phlebotomy visits (blood donation up to 50cc, \~5 tubes, by a certified mobile phlebotomist at home/location of choice) now available.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2019). Autoimmune Features of Neurodegenerative Disorders. <em>Columbia University</em>. https://clinicaltrials.gov/study/NCT04239079
Vancouver
Anonymous. Autoimmune Features of Neurodegenerative Disorders. Columbia University. 2019.
BibTeX
@misc{anon2019Autoim,
title = {Autoimmune Features of Neurodegenerative Disorders},
author = {Anonymous},
journal = {Columbia University},
year = {2019},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Neurogen Biomarking LLC 2025
Open access · US-GOV
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Asan Foundation 2017
Open access · US-GOV
A Phase I [18F]THK-5351 Positron Emission Computed Tomography Study of Biodistribution, Pharmacokinetics and Safety in Cognitively Healthy Subjects and Patients With Alzheimer's Disease
AbbVie 2014
Open access · US-GOV
A Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
University of Wisconsin, Madison 2015
Open access · US-GOV
Aerobic Exercise for Alzheimer's Disease Prevention in At-Risk Middle-Aged Adults
Novartis Pharmaceuticals 2021
Open access · US-GOV
Exploratory PLatform Trial on Anti-Inflammatory Agents in Alzheimer's Disease (EXPLAIN-AD): A Randomized, Placebo-controlled, Multicenter Platform Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Various Anti-inflammatory Agents in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
US Department of Veterans Affairs 1999
Open access · US-GOV